- Home
- AKTX vs FTHM Comparison
AKTX vs FTHM Comparison
Compare AKTX & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- FTHM
- Stock Information
- Founded
- AKTX N/A
- FTHM 2010
- Country
- AKTX United States
- FTHM United States
- Employees
- AKTX 12
- FTHM N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- AKTX Health Care
- FTHM Finance
- Exchange
- AKTX Nasdaq
- FTHM Nasdaq
- Market Cap
- AKTX 35.7M
- FTHM 33.6M
- IPO Year
- AKTX N/A
- FTHM 2020
- Fundamental
- Price
- AKTX $1.14
- FTHM $1.27
- Analyst Decision
- AKTX
- FTHM Buy
- Analyst Count
- AKTX 0
- FTHM 1
- Target Price
- AKTX N/A
- FTHM $2.50
- AVG Volume (30 Days)
- AKTX 25.6K
- FTHM 89.4K
- Earning Date
- AKTX 08-18-2025
- FTHM 08-11-2025
- Dividend Yield
- AKTX N/A
- FTHM N/A
- EPS Growth
- AKTX N/A
- FTHM N/A
- EPS
- AKTX N/A
- FTHM N/A
- Revenue
- AKTX N/A
- FTHM $357,816,000.00
- Revenue This Year
- AKTX N/A
- FTHM $32.40
- Revenue Next Year
- AKTX N/A
- FTHM $18.04
- P/E Ratio
- AKTX N/A
- FTHM N/A
- Revenue Growth
- AKTX N/A
- FTHM 5.80
- 52 Week Low
- AKTX $0.85
- FTHM $0.65
- 52 Week High
- AKTX $4.40
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- AKTX 43.82
- FTHM 53.30
- Support Level
- AKTX $1.10
- FTHM $1.27
- Resistance Level
- AKTX $1.18
- FTHM $1.39
- Average True Range (ATR)
- AKTX 0.05
- FTHM 0.10
- MACD
- AKTX 0.00
- FTHM 0.01
- Stochastic Oscillator
- AKTX 39.52
- FTHM 61.54
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.